Immunotherapy Approaches for Urothelial Bladder Cancer: Expert Guidance Through Challenging Cases Exploring the Fundamental Changes in Patient Care

In this downloadable slideset, Elizabeth R. Plimack, MD, MS, discusses the current clinical rationale and most recent data on immune checkpoint inhibitors for patients with advanced bladder cancer. Click here to use our online tool to see how to select optimal therapy for your patients.
Format: Microsoft PowerPoint (.ppt)
File Size: 7.79 MB
Released: April 30, 2018


Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
PIM Logo

Postgraduate Institute for Medicine
304 Inverness Way South, Suite 100
Englewood, CO 80112

Allison Hughes, CCMEP, Program Manager
(303) 799-1930
(303) 858-8842 (Fax)

This activity is supported by an educational grant from
Merck & Co., Inc.

Related Content

Analysis of phase III IMpower132 trial evaluating the addition of atezolizumab to first-line chemotherapy in NSCLC: PFS, safety, and interim OS.

Released: September 28, 2018

Results from phase I/III IMpower133 trial evaluating addition of atezolizumab to first-line chemotherapy in extensive-stage SCLC from WCLC 2018 reported by Clinical Care Options (CCO).

Released: September 28, 2018

Results from PACIFIC trial of durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC from WCLC 2018 reported by Clinical Care Options (CCO).

Released: September 28, 2018

Interim analysis of the phase III ALTA-1L trial of brigatinib vs crizotinib in ALK inhibitor–naive patients with ALK-positive advanced NSCLC

Released: September 27, 2018

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Welcome to the CCO site.

You are accessing CCO's educational content today as a Guest user.

If you would like to continue with free, full access to the CCO Web sites, including free CME/CE credits, please click the button below.


More info

CCO’s educational programs are available completely free of charge on the,, and Web sites. Certain features and functions are restricted for Guest users. By consenting to become a full member, you are eligible to receive CME/CE credit or participation certificates from certified activities, to register for CCO’s free live meetings and webinars, and to receive CCO’s email newsletters alerting you to new content. You can unsubscribe from our emails at any time. CCO strictly protects the privacy of our members, according to our privacy policy.

A confirmation email will be sent to . Not You?